Edwards Lifesciences (EW)

We have been managing a position in Boston Scientific (NYSE:BSX) since early mid-February of this year. BSX is a medical device company that manufactures coronary stent systems, cancer treatment catheter systems, Parkinson’s deep brain stimulation systems and more.

7 Healthcare Stocks That Are Coming to Life

By Anthony Mirhaydari, InvestorPlace Market Strategist Jul 23, 2018

These seven healthcare stocks are coming to life Monday. Here's how to play these companies without getting burnt.

3 Stocks to Watch on Wednesday: Edwards Lifesciences Corp (EW), Illumina, Inc. (ILMN) and Tesla Inc (TSLA)

By Karl Utermohlen, InvestorPlace Writer Apr 25, 2018

Edwards Lifesciences (EW) and Illumina (ILMN) reported their quarterly earnings results, while Tesla (TSLA) is being accused of stiffing its workers of overtime.

7 Rock-Solid Stocks to Hold On for Dear Life

By Harriet Lefton, Writer, TipRanks Feb 12, 2018

In such fragile market conditions, it pays to keep your portfolio full of solid stocks with consistent growth and a favorable outlook. All of the seven stocks to buy in this article are up on a one-month basis. Some of them by over 10%!

3 Stocks to Watch on Friday: Amgen, Inc. (AMGN), Edwards Lifesciences Corp (EW) and Motorola Solutions Inc (MSI)

By Karl Utermohlen, InvestorPlace Writer Feb 2, 2018

Amgen (AMGN) posted underwhelming earnings, Edwards Lifesciences (EW) posts strong 2017 revenue and Motorola Solutions (MSI) expects 2018 EPS to beat estimates.

The 10 Most Expensive Stocks In The S&P 500

By Matt Hogan, Founder, Finbox.io Jan 24, 2018

These ten stocks are currently the most expensive stocks trading on the S&P 500 -- so buyer beware.

Edwards Lifesciences (EW) Ranking Raised to Buy on Robust Earnings Growth

By Portfolio Grader Dec 12, 2017

Edwards Lifesciences (NYSE:EW) is ranked as a Buy using the methodology for investing of Louis Navellier and his Portfolio Grader stock evaluator. The shares have been upgraded from a Hold to a Buy in the last week.

Edwards Lifesciences (EW) Upgraded to Buy on Improving Sales Growth

By Portfolio Grader Dec 5, 2017

Portfolio Grader currently ranks Edwards Lifesciences (NYSE:EW) a Buy. The approach to fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. EW has been upgraded from a Hold to a Buy in the last week.

Industry Group Rank Metrics Limit Edwards Lifesciences (EW) Ratings Upgrade to Hold

By Portfolio Grader Nov 7, 2017

With a $21.7 billion market value, Edwards Lifesciences (NYSE:EW) ranks in the top 10% of its industry group, Health Care Equipment & Supplies, and in the top 10% of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the ranking for EW by Portfolio Grader places it 76 among the 164 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 366 among the 785 companies in the sector, and number 2,386 in the nearly 5,000 company Portfolio Grader universe.